SynthesisJournal of global health2026
Impact of diabetes mellitus on drug-resistant tuberculosis across resistance categories: a systematic review and meta-analysis.
Synthesis in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) and diabetes mellitus (DM) are major global health challenges that frequently coexist. DM has been associated with adverse TB outcomes, but its relationship with specific categories of drug-resistant TB has not been comprehensively synthesised. The association between DM and different drug-resistance categories in patients with TB was quantified, with a primary focus on resistance to first-line anti-TB drugs. Methods: A systematic review and meta-analysis of observational studies was conducted, drawing on evidence identified through seven international and Chinese databases, in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Study quality was assessed using the Newcastle-Ottawa Scale and the Agency for Healthcare Research and Quality checklist. Random-effects models were used to pool odds ratios (ORs) and 95% confidence intervals (CIs). Results: Forty-five studies involving 51 982 participants were included. Compared with patients without DM, those with DM had higher odds of isoniazid-resistant TB (OR = 1.30; 95% CI = 1.14-1.48), rifampicin-resistant TB (OR = 1.37; 95% CI = 1.17-1.59), and multidrug-resistant TB (OR = 1.45; 95% CI = 1.12-1.88). Associations for polydrug-resistant TB and extensively drug-resistant TB were imprecise and were based on relatively few studies. Subgroup analyses suggested possible geographic variation, although the evidence base was heavily concentrated in East Asia. Exploratory analyses of studies reporting glycaemic data suggested that poorer glycaemic control may be associated with higher odds of drug resistance, but definitions and thresholds were inconsistent across studies. Conclusions: DM was associated with higher odds of isoniazid-resistant TB, rifampicin-resistant TB, and multidrug-resistant TB. These findings should be interpreted as associations rather than evidence of causality, but they support closer integration of TB and DM assessment in clinical care and public health practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.